Cargando…

An Update on African Trypanocide Pharmaceutics and Resistance

African trypanosomiasis is associated with Trypanosoma evansi, T. vivax, T. congolense, and T. brucei pathogens in African animal trypanosomiasis (AAT) while T. b gambiense and T. b rhodesiense are responsible for chronic and acute human African trypanosomiasis (HAT), respectively. Suramin sodium su...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasozi, Keneth Iceland, MacLeod, Ewan Thomas, Ntulume, Ibrahim, Welburn, Susan Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959112/
https://www.ncbi.nlm.nih.gov/pubmed/35356785
http://dx.doi.org/10.3389/fvets.2022.828111
_version_ 1784677077995225088
author Kasozi, Keneth Iceland
MacLeod, Ewan Thomas
Ntulume, Ibrahim
Welburn, Susan Christina
author_facet Kasozi, Keneth Iceland
MacLeod, Ewan Thomas
Ntulume, Ibrahim
Welburn, Susan Christina
author_sort Kasozi, Keneth Iceland
collection PubMed
description African trypanosomiasis is associated with Trypanosoma evansi, T. vivax, T. congolense, and T. brucei pathogens in African animal trypanosomiasis (AAT) while T. b gambiense and T. b rhodesiense are responsible for chronic and acute human African trypanosomiasis (HAT), respectively. Suramin sodium suppresses ATP generation during the glycolytic pathway and is ineffective against T. vivax and T. congolense infections. Resistance to suramin is associated with pathogen altered transport proteins. Melarsoprol binds irreversibly with pyruvate kinase protein sulfhydryl groups and neutralizes enzymes which interrupts the trypanosome ATP generation. Melarsoprol resistance is associated with the adenine-adenosine transporter, P2, due to point mutations within this transporter. Eflornithine is used in combination with nifurtimox. Resistance to eflornithine is caused by the deletion or mutation of TbAAT6 gene which encodes the transmembrane amino acid transporter that delivers eflornithine into the cell, thus loss of transporter protein results in eflornithine resistance. Nifurtimox alone is regarded as a poor trypanocide, however, it is effective in melarsoprol-resistant gHAT patients. Resistance is associated with loss of a single copy of the genes encoding for nitroreductase enzymes. Fexinidazole is recommended for first-stage and non-severe second-stage illnesses in gHAT and resistance is associated with trypanosome bacterial nitroreductases which reduce fexinidazole. In AAT, quinapyramine sulfate interferes with DNA synthesis and suppression of cytoplasmic ribosomal activity in the mitochondria. Quinapyramine sulfate resistance is due to variations in the potential of the parasite's mitochondrial membrane. Pentamidines create cross-links between two adenines at 4–5 pairs apart in adenine-thymine-rich portions of Trypanosoma DNA. It also suppresses type II topoisomerase in the mitochondria of Trypanosoma parasites. Pentamidine resistance is due to loss of mitochondria transport proteins P2 and HAPT1. Diamidines are most effective against Trypanosome brucei group and act via the P2/TbAT1 transporters. Diminazene aceturate resistance is due to mutations that alter the activity of P2, TeDR40 (T. b. evansi). Isometamidium chloride is primarily employed in the early stages of trypanosomiasis and resistance is associated with diminazene resistance. Phenanthridine (homidium bromide, also known as ethidium bromide) acts by a breakdown of the kinetoplast network and homidium resistance is comparable to isometamidium. In humans, the development of resistance and adverse side effects against monotherapies has led to the adoption of nifurtimox-eflornithine combination therapy. Current efforts to develop new prodrug combinations of nifurtimox and eflornithine and nitroimidazole fexinidazole as well as benzoxaborole SCYX-7158 (AN5568) for HAT are in progress while little comparable progress has been done for the development of novel therapies to address trypanocide resistance in AAT.
format Online
Article
Text
id pubmed-8959112
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89591122022-03-29 An Update on African Trypanocide Pharmaceutics and Resistance Kasozi, Keneth Iceland MacLeod, Ewan Thomas Ntulume, Ibrahim Welburn, Susan Christina Front Vet Sci Veterinary Science African trypanosomiasis is associated with Trypanosoma evansi, T. vivax, T. congolense, and T. brucei pathogens in African animal trypanosomiasis (AAT) while T. b gambiense and T. b rhodesiense are responsible for chronic and acute human African trypanosomiasis (HAT), respectively. Suramin sodium suppresses ATP generation during the glycolytic pathway and is ineffective against T. vivax and T. congolense infections. Resistance to suramin is associated with pathogen altered transport proteins. Melarsoprol binds irreversibly with pyruvate kinase protein sulfhydryl groups and neutralizes enzymes which interrupts the trypanosome ATP generation. Melarsoprol resistance is associated with the adenine-adenosine transporter, P2, due to point mutations within this transporter. Eflornithine is used in combination with nifurtimox. Resistance to eflornithine is caused by the deletion or mutation of TbAAT6 gene which encodes the transmembrane amino acid transporter that delivers eflornithine into the cell, thus loss of transporter protein results in eflornithine resistance. Nifurtimox alone is regarded as a poor trypanocide, however, it is effective in melarsoprol-resistant gHAT patients. Resistance is associated with loss of a single copy of the genes encoding for nitroreductase enzymes. Fexinidazole is recommended for first-stage and non-severe second-stage illnesses in gHAT and resistance is associated with trypanosome bacterial nitroreductases which reduce fexinidazole. In AAT, quinapyramine sulfate interferes with DNA synthesis and suppression of cytoplasmic ribosomal activity in the mitochondria. Quinapyramine sulfate resistance is due to variations in the potential of the parasite's mitochondrial membrane. Pentamidines create cross-links between two adenines at 4–5 pairs apart in adenine-thymine-rich portions of Trypanosoma DNA. It also suppresses type II topoisomerase in the mitochondria of Trypanosoma parasites. Pentamidine resistance is due to loss of mitochondria transport proteins P2 and HAPT1. Diamidines are most effective against Trypanosome brucei group and act via the P2/TbAT1 transporters. Diminazene aceturate resistance is due to mutations that alter the activity of P2, TeDR40 (T. b. evansi). Isometamidium chloride is primarily employed in the early stages of trypanosomiasis and resistance is associated with diminazene resistance. Phenanthridine (homidium bromide, also known as ethidium bromide) acts by a breakdown of the kinetoplast network and homidium resistance is comparable to isometamidium. In humans, the development of resistance and adverse side effects against monotherapies has led to the adoption of nifurtimox-eflornithine combination therapy. Current efforts to develop new prodrug combinations of nifurtimox and eflornithine and nitroimidazole fexinidazole as well as benzoxaborole SCYX-7158 (AN5568) for HAT are in progress while little comparable progress has been done for the development of novel therapies to address trypanocide resistance in AAT. Frontiers Media S.A. 2022-03-07 /pmc/articles/PMC8959112/ /pubmed/35356785 http://dx.doi.org/10.3389/fvets.2022.828111 Text en Copyright © 2022 Kasozi, MacLeod, Ntulume and Welburn. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Veterinary Science
Kasozi, Keneth Iceland
MacLeod, Ewan Thomas
Ntulume, Ibrahim
Welburn, Susan Christina
An Update on African Trypanocide Pharmaceutics and Resistance
title An Update on African Trypanocide Pharmaceutics and Resistance
title_full An Update on African Trypanocide Pharmaceutics and Resistance
title_fullStr An Update on African Trypanocide Pharmaceutics and Resistance
title_full_unstemmed An Update on African Trypanocide Pharmaceutics and Resistance
title_short An Update on African Trypanocide Pharmaceutics and Resistance
title_sort update on african trypanocide pharmaceutics and resistance
topic Veterinary Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959112/
https://www.ncbi.nlm.nih.gov/pubmed/35356785
http://dx.doi.org/10.3389/fvets.2022.828111
work_keys_str_mv AT kasozikenethiceland anupdateonafricantrypanocidepharmaceuticsandresistance
AT macleodewanthomas anupdateonafricantrypanocidepharmaceuticsandresistance
AT ntulumeibrahim anupdateonafricantrypanocidepharmaceuticsandresistance
AT welburnsusanchristina anupdateonafricantrypanocidepharmaceuticsandresistance
AT kasozikenethiceland updateonafricantrypanocidepharmaceuticsandresistance
AT macleodewanthomas updateonafricantrypanocidepharmaceuticsandresistance
AT ntulumeibrahim updateonafricantrypanocidepharmaceuticsandresistance
AT welburnsusanchristina updateonafricantrypanocidepharmaceuticsandresistance